Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder

OBJECTIVE: Many patients with major depressive disorder (MDD) suffer from residual symptoms without achieving remission. However, pharmacologic options for residual symptoms of MDD have been limited. This study aimed to investigate benefit of aripiprazole augmentation in the treatment of residual sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Cheolmin, Pae, Chi-Un, Kwak, Kyung Phil, Jeon, Sang Won, Jeong, Hyun-Ghang, Kim, Jong-Woo, Lee, Youn Jung, Patkar, Ashwin A., Han, Changsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Neuropsychopharmacology 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077065/
https://www.ncbi.nlm.nih.gov/pubmed/33888653
http://dx.doi.org/10.9758/cpn.2021.19.2.243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077065/
https://www.ncbi.nlm.nih.gov/pubmed/33888653
http://dx.doi.org/10.9758/cpn.2021.19.2.243

Ejemplares similares